Ind-Swift (INDSWFTLTD) Stock Overview

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynaecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-allergic, neurology, and oncology. The company also provides Ayurvedic products, as well as contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries, as well as licenses its products to the United Kingdom, Europe, Canada, and Australia. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.